Search

everythinglearnresearchcommunity

for

Search:↓

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.

Ruxolitinib helped a man regrow his beard after years of hair loss.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

JAK inhibitors are effective treatments for alopecia areata.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

PXX is an effective and affordable photocatalyst for creating new chemical bonds in organic synthesis.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Platelet-rich fibrin speeds up burn wound healing in rabbits.

A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

A woman with severe angioedema improved significantly after treatment with rituximab.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Bortezomib chemotherapy can cause temporary skin rashes.

Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Alefacept may effectively treat severe lichen planus, with patients showing significant improvement and no side effects.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Platelet Rich Plasma reduces psoriasis symptoms but isn't enough alone for treatment.